SWOG S1400C:Palbociclib治疗既往治疗过的细胞周期基因改变阳性IV期鳞状细胞肺癌的II期研究
Lung-MAP平台子研究S1400C评估Palbociclib在细胞周期基因改变的鳞状NSCLC患者中的疗效。32例可评估患者中,部分缓解2例(6% [95%CI: 0%-15%]),疾病稳定12例(38% [95%CI: 21%-54%]),中位PFS 1.7个月,中位OS 7.1个月。Palbociclib单药未达到预设的进入III期研究标准。
要点
- Palbociclib在CDK4/CCND1/2/3扩增的鳞状NSCLC中客观缓解率仅6%。
- 中位PFS 1.7个月,中位OS 7.1个月,未达到预设推进III期的标准。
- 筛查患者中仅9%被分配至该子研究,合格接受Palbociclib者32例。
核心结论
- Palbociclib单药在细胞周期基因改变阳性的既往治疗鳞状NSCLC中未达到预设的进入III期研究标准。
研究设计与样本
- Lung-MAP(SWOG S1400)平台试验的子研究S1400C,原设计为比较Palbociclib与多西他赛的II/III期试验,后改为单臂II期试验,主要终点为缓解率。
- 入组患者为鳞状NSCLC、体能状态0-2、器官功能正常、至少一线含铂化疗后进展且肿瘤标本存在CDK4或CCND1/2/3扩增。
- 若前20例患者中缓解不超过2例则停止入组;共88例(筛查患者的9%)被分配至S1400C,53例入组(其中17例接受多西他赛)。
- 合格接受Palbociclib的患者32例,基因改变频率为CCND1 81%(26例)、CCND2 9%(3例)、CCND3 6%(2例)、CDK4 3%(1例)。
主要发现
- 32例合格接受Palbociclib的患者中,部分缓解2例(缓解率6% [95%CI: 0%-15%]),均为CCND1扩增。
- 12例患者疾病稳定(38% [95%CI: 21%-54%])。
- 中位无进展生存期1.7个月(95%CI: 1.6-2.9个月),中位总生存期7.1个月(95%CI: 4.2-12.5个月)。
关键数值与推荐
- 主要终点缓解率6%(95%CI: 0%-15%),未达到预设的进入III期研究标准。
- 疾病稳定率38%(95%CI: 21%-54%)。
- 中位无进展生存期1.7个月(95%CI: 1.6-2.9个月),中位总生存期7.1个月(95%CI: 4.2-12.5个月)。
临床怎么用
- Palbociclib单药不推荐用于CDK4/CCND1/2/3扩增的既往治疗鳞状NSCLC。
- 细胞周期基因改变(尤其CCND1扩增)在该人群中常见,但未转化为显著临床获益。
局限性
- 研究为单臂II期设计,样本量小(32例合格接受Palbociclib),未设同期对照。
- 原设计因免疫治疗获批而修改,部分入组患者接受多西他赛,可能影响解释。
- 筛查人群中仅9%被分配至该子研究,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lung-MAP (SWOG S1400) is a master platform trial assessing targeted therapies in squamous NSCLC. The objective of study C (S1400C) was to evaluate the response rate to palbociclib, a cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitor, in patients with cell cycle gene abnormalities. METHODS: Patients with squamous NSCLC, a performance status of 0 to 2, and normal organ function who had progressed after at least one prior platinum-based chemotherapy with cyclin-dependent kinase 4 gene (CDK4) or cyclin D1 gene (CCND1), cyclin D2 gene (CCND2), or cyclin D3 gene (CCND3) amplifications on tumor specimens were eligible. The study was originally designed as a phase II/III trial comparing palbociclib with docetaxel, but it was modified to a single-arm phase II trial with the primary end point of response when immunotherapy was approved. If two or fewer responses were seen in the first 20 patients, then the study would cease enrollment. RESULTS: A total of 88 patients (9% of patients screened) were assigned to S1400C, and 53 patients enrolled (including 17 to receive docetaxel). One patient who had been registered to receive docetaxel was re-registered to receive palbociclib after progression while taking docetaxel. The frequencies of cell cycle gene alterations in the eligible patients taking palbociclib (n = 32) were as follows: CCND1, 81% (n = 26); CCND2, 9% (n = 3); CCND3, 6% (n = 2); and CDK4, 3% (n = 1). In all, 32 eligible patients received palbociclib. There were two partial responses (response rate 6% [95% confidence interval (CI): 0%-15%]), both with CCND1 amplification. Twelve patients had stable disease (38% [95% CI: 21%-54%]). The median progression-free survival was 1.7 months (95% CI: 1.6-2.9 months) and the median overall survival was 7.1 months (95% CI: 4.2-12.5). CONCLUSION: Palbociclib as monotherapy failed to demonstrate the prespecified criteria for advancement to phase III testing.
引用
- Edelman MJ, Redman MW, Albain KS, et al. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019. PMID: 31302234. doi:10.1016/j.jtho.2019.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。